Deep Anterior Lamellar Keratoplasty (DALK) Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients

Deep Anterior Lamellar Keratoplasty Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01021046

Enrollment

Registered

2009-11-26

Start date

2006-12-31

Completion date

2010-07-31

Last updated

2010-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Anterior Lamellar Keratoplasty, Glycerin Cryopreserved Acellular Corneal Tissue, High Risk Keratoplasty

Keywords

deep anterior lamellar keratoplasty, rejection, high risk patients, acellular corneal tissue

Brief summary

The purpose of this study is to study whether deep anterior lamellar keratoplasty (DALK) using acellular tissue will promote corneal graft survival in high risk patients.

Interventions

PROCEDUREDALK using GCCT

Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue

PROCEDUREDALK using FCT

Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* severe bacterial keratitis * Herpes simplex keratitis * severe fungal keratitis * partial limbal deficiency after chemical burn

Exclusion criteria

* posterior stroma involved in severe bacterial and fungal keratitis * dry eye * glaucoma or intraocular pressure greater than 21 mmHg * amblyopia * retinal abnormalities * patients with severe systemic diseases not good for ocular surgery

Design outcomes

Primary

Measure	Time frame
rejection	—

Secondary

Measure	Time frame
laser scanning in vivo confocal microscopy	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026